Signablok
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
PO Box 4064, Shrewsbury, Massachusetts, ...Phone Number
(203) 505-3807Website
www.signablok.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Signablok
SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems through the use of the company's revolutionary science and technologies, the company offers high quality innovation, science and management expertise, encouraging results, an impressive IP portfolio, and growing involvement in international research. The company's pioneering research efforts focus on four core therapeutic areas: cancer, atherosclerosis, inflammatory and immune diseases.Explore more
Signablok Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Signablok your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Signablok is spiking on competitors!
Funding: Get notified immidiatlly once Signablok has new funding data
Congratulate Masked Content for being promoted to Masked Content at Signablok
Signablok, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Signablok recently announced quarterly report
Product Launch: Get notified when Signablok launches new products
Website visits: Recent activity has been detected on your website
Check if Signablok has recently received funding, and reach out quickly before it becomes old news!
Click to see if Signablok had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Signablok
Find 3 more new buyers
Compare Similar Companies to Signablok
Compare insights from companies similar to Signablok, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Signablok is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Signablok is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Signablok.
Signablok Tech Stack
A closer look at the technologies used by Signablok
See more technologies
Signablok News & Media
SignaBlok to Present Novel Approach to Preventing Cancer Recurrence at the 2026 American Association for Cancer Research (AACR) Annual Meeting
• In experimental pancreatic cancer, macrophage-targeted but not cell-unspecific TREM-1 inhibitor: 1) prevents cancer recurrence, improves complete response rate and survival, when administered in a time window of 7 days after standard-of-care (SOC) chemotherapy, and 2) reverses immunosuppression and overcomes cancer resistance to anti-PD-L1 immunotherapy [PR.com]SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug for the Treatment of Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of hard-to-treat cancers. In combination with standard-of-care chemotherapy, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, prevents cancer recurrence, improves complete response rate and survival in experimental pancreatic cancer. In combination with anti-PD-L1 treatment, it overcomes [PR.com]SignaBlok to Present Preclinical Data on TREM-1-Targeting Drug at the Respiratory Innovation Summit and American Thoracic Society International Conference 2025
SignaBlok will present positive preclinical data on targeting innate inflammation for the treatment of sepsis and pulmonary diseases. In experimental sepsis, SignaBlok's new mechanism-based inhibitor of TREM-1, an inflammation amplifier, protects from death with the level of protection not declining at delayed treatment times. In pulmonary inflammation and fibrosis in rats and mice, it reduces neutrophil infiltration in [PR.com]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Signablok
Sign Up For FreeTo access detailed company insights
SignaBlok, Inc. is a biopharmaceutical company on a fast track to success. Founded in 2009 to develop novel targeted therapeutics and delivery nanosystems through the use of the company's revolutionary science and technologies, the company offers high quality innovation, science and management expertise, encouraging results, an impressive IP portfo... Read More
